Inclusion Criteria

          -  Part 1: Breast Cancer (BC)

               -  Refractory Hormone Receptor Positive (HR+), Human Epidermal Growth Factor
                  Receptor 2 Negative (HER2-) BC

               -  Part 1A/Part 1D also include: Refractory HR-positive/HER2-positive BC

          -  Part 1: Tumors other than BC (Part 1A/Part 1D): NSCLC, prostate, CRC, liposarcoma, or
             tumors with previously confirmed CDK4 or CCND1 amplification according to local
             standard tests

          -  Part 2:

               -  HR-positive/HER2-negative BC

               -  Patients who are either postmenopausal women or pre/peri-menopausal (Part 2C
                  only)

          -  Lesion:

               -  Part 1: evaluable lesion (including skin or bone lesion only)

               -  Part 2: measurable lesion per RECIST v1.1

          -  Prior systemic Treatment

               -  Part 1: HR-positive/HER2-negative BC

                    -  At least 1 line of SOC, including CD4/6 inhibitor therapy for advanced or
                       metastatic disease, or if CDK4/6 inhibitors are not considered appropriate
                       in the opinion of the investigator

                    -  At least 1 line of anti-endocrine in countries without CDK4/6 inhibitor
                       approval or reimbursement, for advanced or metastatic disease

                    -  HR-positive/HER2-positive BC (Parts 1A/1D): at least 1 prior treatment of
                       approved HER2 targeting therapy

                    -  Tumors other than BC (Parts 1A/1D): tumor that is resistant to at least 2
                       lines of SOC for advanced or recurrent disease or for which no standard
                       therapy is available

               -  Part 2B: participants who have not received any prior systemic anti-cancer
                  therapies for advanced/metastatic BC

               -  Part 2C:

                    -  Progressed during treatment or within 12 months of completion of adjuvant
                       therapy with an aromatase inhibitor if postmenopausal, or tamoxifen if pre
                       or perimenopausal, or

                    -  Progressed while on or within 1 month after the endo the prior aromatase
                       inhibitor therapy for advanced/metastatic BC if postmenopausal or prior
                       endocrine treatment for advanced/metastatic BC if pre or perimenopausal

                    -  One previous line of chemotherapy for advanced/metastatic disease is allowed
                       in addition to endocrine therapy

        General Inclusion Criteria

          -  All participants must be refractory to or intolerant of existing therapies known to
             provide clinical benefit for their condition.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1

          -  Adequate renal, liver, and bone marrow function

        Exclusion Criteria:

          -  Part 1D: participants who have had a gastrectomy or have dietary or other restrictions
             that preclude a 10 hour overnight fast or consumption of the high fat, high calorie
             meal

          -  Part 2B: prior neoadjuvant or adjuvant treatment with a non-steroidal aromatase
             inhibitor with disease recurrence while on or within 12 months of completing
             treatment. Prior treatment with any CDK4/6 inhibitor

          -  Part 2C: prior treatment with any CDK inhibitor, fulvestrant, everolimus, or any agent
             whose mechanism of action is to inhibit the PI3K-mTOR pathway

          -  Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases
             carcinomatous meningitis, or leptomeningeal disease

          -  Other active malignancy within 3 years prior to randomization, except for adequately
             treated basal cell or squamous cell skin cancer, or carcinoma in situ

          -  Major surgery or radiation within 4 weeks prior to study intervention

          -  Last anti-cancer treatment within 2 weeks prior to study intervention

          -  Participation in other studies involving investigational drug(s) within 4 weeks prior
             to study entry

          -  Pregnant or breastfeeding female participant

          -  Active inflammatory gastrointestinal (GI) disease, known diverticular disease or
             previous gastric resection or lap band surgery including impairment of
             gastrointestinal function or GI disease